95.0%(T); Synonyms: 酒石酸伐侖克林, 7,8,9,10-四氫-6H-6,10-甲橋吖庚因并[4,5-g]喹喔啉(2R,3R)-2,3-二羥基丁二酸, 7,8,9,10-四氫-6,10-甲橋-6H-吡嗪并[2,3-h][3]苯并氮雜卓酒石酸鹽, 7,8,9,10-Tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline (2R,3R)-2,3-Dihydroxysuccinic Acid, 7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine Tartrate; Appearance: White to Light yellow to Light orange powder to crystal, min. 95.0 %, min. 98.0 area%, max. 5.0 %, confirm to structure; contact TCI for more">
Varenicline Tartrate: A Partial Agonist/Antagonist with Affinity and Selectivity for α4β2 Nicotinic Acetylcholine Receptors
Varenicline tartrate is a partial agonist/antagonist with affinity and selectivity for α4β2 nicotinic acetylcholine receptors. Varenicline binds to α4β2 neuronal nicotinic acetylcholine receptors and stimulates receptor-mediated activity, but at a significantly lower level than nicotine. In other words, varenicline blocks the ability of nicotine to the receptors (antagonist) and thus to stimulate partially the central nervous mesolimbic dopamine system (partial agonist). In clinical, varenicline tartrate is used as an anti-smoking agent. This receptor stimulation is thought to reduce the withdrawal symptoms associated with smoking cessation and the craving for cigarettes. (The product is for research purpose only.)
References
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation